C3, Equipmed sign distribution agreements
Monday, 27 October, 2003
Perth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
The ReCell agreement will be activated once TGA approval has been obtained for general marketing of the product. The agreements have three year terms and including marketing and support activities.
C3 CEO Troels Jordansen said the company was pleased to have an agreement with Equipmed, which has experience in the plastic and cosmetic surgery market and distributes tissue engineering products from international company Isolagen.
C3 is planning to expand its business internationally next year, with a European production facility in the works and sales of ReCell in 15 companies around the world expected.
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
